WS #10424

From 499 msgs · 10 key-dev

AbbVie pays $10.9B for Apogee, gaining phase 2 atopic dermatitis candidate zumilokibart; earnings accretion not expected until 2032.

AbbVie Acquires Apogee Therapeutics for $10.9B

AbbVie pays $10.9B for Apogee, gaining phase 2 atopic dermatitis candidate zumilokibart; earnings accretion not expected until 2032.

Full world state #10424 →